ReviewProteomics. Clinical applications2016
Proteomics, biomarkers, and HIV-1: A current perspective.
Review in Proteomics. Clinical applications, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Emerging biomarkers for early detection of aplastic anemia in HIV: A narrative review.Medicine · 2026Review
- Proteomic Characterization of HIV Infection.Advances in experimental medicine and biology · 2026Review
- Mediterranean diet adherence is associated with antiviral, neuroimmune, and cardiometabolic proteomic profiles in people with HIV.Frontiers in nutrition · 2026Article
- Neuropathogenesis of acute HIV: mechanisms, biomarkers, and therapeutic approaches.Current opinion in HIV and AIDS · 2025Review
- HIV-2 mediated effects on target and bystander cells induce plasma proteome remodeling.iScience · 2024Article
- Multi-omics in HIV: searching insights to understand immunological non-response in PLHIV.Frontiers in immunology · 2023Review
- Discovery of Dehydroamino Acid Residues in the Capsid and Matrix Structural Proteins of HIV-1.Journal of proteome research · 2022Article
- HIV and Proteomics: What We Have Learned from High Throughput Studies.Proteomics. Clinical applications · 2021Review
- Large-Scale "OMICS" Studies to Explore the Physiopatholgy of HIV-1 Infection.Frontiers in genetics · 2019Review
- Differential Contribution of HIV-1 Subtypes B and C to Neurological Disorders: Mechanisms and Possible Treatments.AIDS reviews · 2019Review
- Article
- Exosome-associated release, uptake, and neurotoxicity of HIV-1 Tat protein.Journal of neurovirology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Despite more than three decades of extensive research, HIV-1 infection although well controlled with cART, remains incurable. Multifactorial complexity of the viral life-cycle poses great challenges in understanding molecular mechanisms underlying this infection and the development of biomarkers, which we hope will lead us to its eradication. For a more in-depth understanding of how the virus interacts with host target cells, T cells and macrophages, proteomic profiling techniques that offer strategies to investigate the proteome in its entirety were employed. Here, we review proteomic studies related to HIV-1 infection and discuss perspectives and limitations of proteomic and systems biology approaches in future studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.